title: [Mineralocorticoid receptor: an update].
abstract: The aldosterone-mineralocorticoid receptor (MR) system is traditionally considered as a system involved in the homeostatic regulation of body fluid and blood pressure in our body. A landmark clinical trial RALES caused a paradigm shift: growing attention has been focused on its role as a mediator of target organ damage. Recent studies clarified novel aspects of MR action in the pathophysiology of cardiac injury, through the analyses of genetically-engineered mice. My group focused on the anti-proteinuric effects of MR antagonist, and examined the role of MR overactivation in the progression of chronic kidney disease, and mechanisms of ligand-independent MR activation. In this paper, I would like to review the recent progress in the field of MR research.
authors.affiliation: Division of Chronic Kidney Disease, Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine.
authors.forename: Miki
authors.initials: M
authors.lastname: Nagase
mesh_terms: D000450:Aldosterone / Q000378:metabolism; D000818:Animals; D006331:Heart Diseases / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology*; D011507:Proteinuria / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000378:metabolism*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D000450:Aldosterone